The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide - Regardless of Etiology and Phenotype

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 10, 2003, Pages 4897-4903

  Vilsboll T ^a,b,f   Knop, F K ^a   Krarup, T ^a   Johansen, A ^c   Madsbad, S ^d   Larsen, S ^e   Hansen, T ^c   Pedersen, O ^c   Holst, J J ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; NUCLEAR FACTOR I; POLYPEPTIDE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; GENE MUTATION; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RESPONSE; MALE; MATURITY ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DNA-BINDING PROTEINS; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 1; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; NUCLEAR PROTEINS; PANCREATITIS; PEPTIDE FRAGMENTS; PHENOTYPE; PROTEIN PRECURSORS; TRANSCRIPTION FACTORS;

EID: 0242383351     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030738     Document Type: Article

References (26)

1. Creutzfeldt W, Nauck M 1992 Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149-177
2. Nauck M, Stockmann F, Ebert R, Creutzfeldt W 1986 Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52
3. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W 1986 Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492-498
4. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ 2001 Reduced post-prandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
5. Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK 1994 The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63-74
6. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type II diabetes mellitus. J Clin Invest 91:301-307
7. Vilsboll T, Krarup T, Madsbad S, Holst JJ 2002 Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111-1119
8. Vilsboll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ 2000 Evaluation of β-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 23:807-812
9. Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA 2001R educed insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50:2497-2504
10. World Health Organization 1999 Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Department of Noncommunicable Disease Surveillance
11. Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, Dimagno EP 1994 The different courses of early-onset and late-onset idiopathic and alcoholic chronic-pancreatitis. Gastroenterology 107:1481-1487
12. Axon ATR, Classen M, Cotton PB, Cremer M, Freeny PC, Lees WR 1984 Pancreatography in chronic-pancreatitis - international definitions. Gut 25: 1107-1112
13. Hansen T, Eiberg H, Rouard M, Vaxillaire M, Moller AM, Rasmussen SK, Fridberg M, Urhammer SA, Holst JJ, Almind K, Echwald SM, Hansen L, Bell GI, Pedersen O 1997 Novel MODY3 mutations in the hepatocyte nuclear factor-1α gene: evidence for a hyperexcitability of pancreatic β-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes 46:726-730
14. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L 1983 Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type 1 (insulin-dependent) diabetics. J Clin Endocrinol Metab 56:1306-1312
15. Krarup T, Holst JJ 1984 The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 9:35-46
16. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539
17. Orskov C, Jeppesen J, Madsbad S, Holst JJ 1991 Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415-423
18. Gallwitz B, Witt M, Morys-Wortmann C, Folsch UR, Schmidt WE 1996 GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1. Regul Pept 63:17-22
19. Goke R, Trautmann ME, Haus E, Richter G, Fehmann HC, Arnold R, Goke B 1989 Signal transmission after GLP-1(7-36)amide binding in RINm5F cells. Am J Physiol 257:G397-G401
20. Gromada J, Holst JJ, Rorsman P 1998 Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 435:583-594
21. Holst JJ, Gromada J, Nauck MA 1997 The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40:984-986
22. Ferrer J 2002 A genetic switch in pancreatic β-cells - implications for differentiation and haploinsufficiency. Diabetes 51:2355-2362
23. Dukes ID, Sreenan S, Roe MW, Levisetti M, Zhou YP, Ostrega D, Bell GI, Pontoglio M, Yaniv M, Philipson L, Polonsky KS 1998 Defective pancreatic β-cell glycolytic signaling in hepatocyte nuclear factor-1α- deficient mice. J Biol Chem 273:24457-24464
24. Shih DQ, Screenan S, Munoz KN, Philipson L, Pontoglio M, Yaniv M, Polonsky KS, Stoffel M 2001 Loss of HNF-1α function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism. Diabetes 50:2472-2480
25. Fehmann HC, Goke R, Goke B 1995 Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390-410
26. Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njolstad PR, Hansen T, Costa A, Conget I, Pedersen O, Sovik O, Lorini R, Groop L, Froguel P, Hattersley AT 2002 The genetic abnormality in the βcell determines the response to an oral glucose load. Diabetologia 45:427-435